Citations

Clear

513 citation(s) found for "Ta, Casey".

Cutaneous sarcoid‐like drug reaction caused by an anaplastic lymphoma kinase inhibitor
Gleue, Casey A. , Shah, Kabeer , Wentworth, Ashley B., Bridges, Alina G. , Wentworth, Ashley, Bridges, Alina

Mayo Clinic

Journal of Cutaneous Pathology | October 31, 2020 | Volume: 48 | Issue: 3 | Pages: 425-428

10.1111/cup.13911 | PMID 33128468 Get It

AbstractAnaplastic lymphoma kinase (ALK) rearranged lung cancers represent 4% to 6% of all pulmonary adenocarcinomas, and echinoderm microtubule associated protein like 4 (EML4)‐ALK fusions are the most common subgroup. Herein, we report a case of two successive drug reactions due to ALK inhibitors. A 69‐year‐old female with stage IVB EML4‐ALK fused lung adenocarcinoma developed a generalized morbilliform eruption 10 days after starting alectinib. Skin biopsy findings were consistent with a drug reaction. Her findings resolved after alectinib was discontinued. Another ALK inhibitor, lorlatinib was started and she developed multiple asymptomatic cutaneous and oral nodules 4 months later. Biopsies from these nodules showed sarcoidal granulomas without evidence of metastases or infection. ALK inhibitors are associated with numerous adverse events, including various cutaneous eruptions. However, a sarcoidal drug reaction involving the skin has not been reported. Identification of drug reactions to targeted therapy can avoid long‐term sequelae and misinterpretation of the clinical findings as disease progression or infection.
Sex-related differences in rapid-onset vasodilation: impact of aging
Hanson, Brady E. , Joyner, Michael J. , Casey, Darren P. , Joyner, Michael J

Mayo Clinic

Journal of Applied Physiology | October 29, 2020 | Volume: 130 | Issue: 1 | Pages: 206-214

10.1152/japplphysiol.00663.2020 | PMID 33119464 Get It

While rapid-onset vasodilation (ROV) has been shown to decrease in older individuals, it is unclear if sex contributes to the decline with aging. We sought to identify if sex-related differences exist in the ROV response to single forearm contractions in young and older adults. Our data suggest sex-related differences are present among older but not young individuals, with women having an attenuated response. These data indicate sex plays a role in decreased vasodilation with aging.
Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group
Lautz, Timothy B. , Li, Minjie , Casey, Dana L. , Routh, Jonathan C. , Granberg, Candace F. , Binite, Odion, Rudzinski, Erin R. , Hawkins, Douglas S. , Venkatramani, Rajkumar , Rodeberg, David A. , Casey, Dana L , Routh, Jonathan C , Hawkins, Douglas S , Lautz, Timothy , Chi, Yueh‐Yun , Wolden, Suzanne L.

Mayo Clinic

Cancer | October 20, 2020 | Volume: 127 | Issue: 2 | Pages: 275-283

10.1002/cncr.33275 | PMID 33079399 Get It

Background Most children with intermediate‐risk rhabdomyosarcoma (RMS) have gross disease (group III) at the initiation of chemotherapy. Delayed primary excision (DPE) after induction chemotherapy allows for a reduction in adjuvant radiation dose, but with the risk of potential surgical morbidity. The objectives of this study were to compare outcomes in children with group III RMS who did and did not undergo DPE and to assess surgical morbidity. Methods The study included 369 patients who had clinical group III RMS at sites amenable to DPE from intermediate‐risk Children's Oncology Group studies D9803 (encouraged DPE) and ARST0531 (discouraged DPE). Results The primary tumor site was bladder/prostate (136 patients; 37%), extremity (97 patients; 26%), trunk (24 patients; 7%), retroperitoneum (91 patients; 25%), or intrathoracic/perineum/perianal (21 patients; 6%). In total, 112 patients (53.9%) underwent DPE in D9803, and 26 patients (16.2%) underwent DPE in ARST0531 ( P < .001), with loss of vital organ or function in 30 of 138 patients (22%). DPE allowed for a reduced radiation dose in 110 of 135 patients (81%; 51% were reduced to 36 Gy, and 30% were reduced to 42 Gy). Patients who underwent DPE had improved unadjusted overall survival ( P = .013). In adjusted regression analysis, the risk of death (hazard ratio, 0.71; 95% CI 0.43‐1.16) was similar for patients who did and did not undergo DPE and was improved for the subset of patients who had tumors of the trunk and retroperitoneum (hazard ratio, 0.44; 95% CI, 0.20‐0.97). Conclusions Children with group III RMS have equivalent or improved outcomes with DPE and can receive a decreased radiation dose for definitive local control. The choice of local control modality should weigh the potential morbidity of surgery versus that of higher dose irradiation.
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology
Hou, Xu , Cook, Casey , Liu, Chia‐Chen , Kang, Silvia S. , Lin, Wen‐Lang, DeTure, Michael , Diehl, Nancy N. , Al‐Shaikh, Fadi S. Hanna , Walton, Ronald L., Ross, Owen A. , Melrose, Heather L. , Ertekin‐Taner, Nilüfer , Bu, Guojun , Petrucelli, Leonard , Fryer, John Denis , Murray, Melissa E. , Fiesel, Fabienne C. , Springer, Wolfdieter , Watzlawik, Jens O. , Al-Shaikh, Fadi S Hanna, Liu, Chia-Chen , Ross, Owen A , Bu, Guojun , Fiesel, Fabienne C , Springer, Wolfdieter , Murray, Melissa E , Hou, Xu , Heckman, Michael G. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2020 | Volume: 17 | Issue: 3 | Pages: 417-430

10.1002/alz.12198 | PMID 33090691 Get It

Abstract Introduction The cytoprotective PTEN‐induced kinase 1 (PINK1)‐parkin RBR E3 ubiquitin protein ligase (PRKN) pathway selectively labels damaged mitochondria with phosphorylated ubiquitin (pS65‐Ub) for their autophagic removal (mitophagy). Because dysfunctions of mitochondria and degradation pathways are early features of Alzheimer's disease (AD), mitophagy impairments may contribute to the pathogenesis. Methods Morphology, levels, and distribution of the mitophagy tag pS65‐Ub were evaluated by biochemical analyses combined with tissue and single cell imaging in AD autopsy brain and in transgenic mouse models. Results Analyses revealed significant increases of pS65‐Ub levels in AD brain, which strongly correlated with granulovacuolar degeneration (GVD) and early phospho‐tau deposits, but were independent of amyloid beta pathology. Single cell analyses revealed predominant co‐localization of pS65‐Ub with mitochondria, GVD bodies, and/or lysosomes depending on the brain region analyzed. Discussion Our study highlights mitophagy alterations in AD that are associated with early tau pathology, and suggests that distinct mitochondrial, autophagic, and/or lysosomal failure may contribute to the selective vulnerability in disease.
Pre‐operative patella alta does not affect midterm clinical outcomes and survivorship of patellofemoral arthroplasty
Bernard, Christopher D. , Pareek, Ayoosh , Sabbag, Casey M. , Parkes, Chad W. , Krych, Aaron J. , Cummings, Nancy M. , Dahm, Diane L., Krych, Aaron J

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | September 24, 2020 | Volume: 29 | Issue: 5 | Pages: 1670-1677

10.1007/s00167-020-06205-z | PMID 32970202 Get It

AbstractPurposeThe purpose of this study was to evaluate the effect of preoperative patella alta on clinical outcomes, survivorship, and complication and reoperation rates on patellofemoral arthroplasty (PFA).MethodsAll patients who underwent PFA for isolated patellofemoral arthritis by a single surgeon at our institution were identified. Preoperative radiographs were measured by two independent observers for patellar height using the Caton Deschamps (CD), Insall‐Salvati (IS), and Blackburne‐Peele (BP) methods. Patients were classified as either “patella alta” or “non‐patella alta” for all three measurement methods. Clinical scores including KSS Pain, KSS Function, and Tegner Activity Scores were collected pre‐ and post‐operatively. Failure was defined as conversion to total knee arthroplasty (TKA). Clinical outcomes and survivorship were compared between patients with “patella alta” and “non‐patella alta” height measurements.ResultsThere were 119 patients with 153 knees (86% female) included in the study with a mean age of 55.8 years. Outcome scores improved from pre‐operative to post‐operative for both patella alta and non‐patella alta patients for Tegner, KSS pain and KSS function scores. The mean change in Tegner scores for patella alta and non‐patella alta patients were not significantly different for CD (p = 0.24), IS (p = 0.25) or BP measurements (p = 0.39). The mean change in KSS pain scores between groups were not significantly different for CD (p = 0.33) or IS measurements (p = 0.22), but was improved more significantly in patella alta patients vs non‐patella alta patients (21.2 and 14.4; p = 0.02) for BP measurement. The mean change in KSS function scores between groups was not significantly different for CD (p = 0.61) IS (p = 0.90) or BP measurements (p = 0.79). The overall survivorship from conversion to total knee arthroplasty (TKA) was 94.1% at a mean follow‐up time of 5.0 (SD 2.6) years. There were no significant differences in survivorship from TKA between patella alta and non‐patella alta groups (CD: p = 0.72, IS: p = 0.63, BP: p = 0.66).ConclusionsThis study suggests that there are no significant differences in clinical outcome scores or survivorship from TKA between patella alta and non‐patella alta patients who underwent onlay design PFA. Both patella alta and non‐patella alta patients demonstrated excellent improvement in outcome scores from pre‐operative to post‐operative.Level of evidenceIV.
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
Innocenti, Federico , Sibley, Alexander B. , Patil, Sushant, Etheridge, Amy S. , Jiang, Chen , Ou, Fang‐Shu , Howell, Stefanie , Plummer, Sarah J. , Bertagnolli, Monica M. , McLeod, Howard L. , Auman, J. Todd , Blanke, Charles D. , Furukawa, Yoichi , Kubo, Michiaki , Lenz, Heinz‐Josef , Ratain, Mark J. , Owzar, Kouros , Bertagnolli, Monica M , McLeod, Howard L , Auman, James T , Furukawa, Yoichi , Venook, Alan P , Kubo, Michiaki , Lenz, Heinz-Josef , Parker, Joel S , Ou, Fang-Shu , Casey, Graham , Venook, Alan P. , Parker, Joel S.

Mayo Clinic

Clinical Cancer Research | September 21, 2020 | Volume: 27 | Issue: 1 | Pages: 267-275

10.1158/1078-0432.ccr-20-2021 | PMID 32958699 Get It

Abstract Purpose: Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. Experimental Design: Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. Results: The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 (MGST1) and LIM domain only 3 (LMO3, representative HR, 1.56; P = 1.30 × 10−6), and rs11644916 in AXIN1 (HR, 1.39, P = 4.26 × 10−6). AXIN1 is a well-established tumor suppressor gene in colorectal cancer, and rs11644916 (G&gt;A) conferred shorter OS. Median OS for patients with the AA, AG, or GG genotypes was 18.4, 25.6, or 36.4 months, respectively. In 90 patients with stage IV colorectal cancer from The Cancer Genome Atlas (TCGA), rs11649255 in AXIN1 [in almost complete linkage disequilibrium (LD) with rs11644916], was associated with shorter OS (HR, 2.24, P = 0.0096). Using rs11648673 in AXIN1 (in very high LD with rs11644916 and with functional evidence), luciferase activity in three colorectal cancer cell lines was reduced. Conclusions: This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.
Treatment of urethral stricture disease in women: A multi‐institutional collaborative project from the SUFU research network
Lane, Giulia I. , Smith, Ariana L. , Stambakio, Hanna, Lin, George, Alawamlh, Omar Al Hussein, Anger, Jennifer T. , Brandes, Eileen R., Carmel, Maude , Chung, Doreen E. , Cox, Lindsey , DeLong, Jessica , Eltahawy, Ehab , França, Wagner, Gousse, Angelo E., Gupta, Priyanka , Hagedorn, Judith C. , High, Rachel , Khan, Aqsa , Kowalik, Casey G. , Lee, Richard K., Lucioni, Alvaro , MacDonald, Susan M. , Malaeb, Bahaa S., McKay, Scotty, Padmanabhan, Priya , Powell, Charles R., Sajadi, Kamran P. , Sutherland, Suzette E. , Theva, Didi , Vollstedt, Annah , Welk, Blayne , Zheng, Yu , Cameron, Anne P. , Carmel, Maude E , Elliott, Christopher S , Sajadi, Kamran P , Vollstedt, Annah , Welk, Blayne , Lee, Una J

Mayo Clinic

Neurourology and Urodynamics | September 19, 2020 | Volume: 39 | Issue: 8 | Pages: 2433-2441

10.1002/nau.24507 | PMID 32926460 Get It

Abstract Aim Female urethral stricture disease is rare and has several surgical approaches including endoscopic dilations (ENDO), urethroplasty with local vaginal tissue flap (ULT) or urethroplasty with free graft (UFG). This study aims to describe the contemporary management of female urethral stricture disease and to evaluate the outcomes of these three surgical approaches. Methods This is a multi‐institutional, retrospective cohort study evaluating operative treatment for female urethral stricture. Surgeries were grouped into three categories: ENDO, ULT, and UFG. Time from surgery to stricture recurrence by surgery type was analyzed using a Kaplan–Meier time to event analysis. To adjust for confounders, a Cox proportional hazard model was fit for time to stricture recurrence. Results Two‐hundred and ten patients met the inclusion criteria across 23 sites. Overall, 64% ( n = 115/180) of women remained recurrence free at median follow‐up of 14.6 months (IQR, 3–37). In unadjusted analysis, recurrence‐free rates differed between surgery categories with 68% ENDO, 77% UFG and 83% ULT patients being recurrence free at 12 months. In the Cox model, recurrence rates also differed between surgery categories; women undergoing ULT and UFG having had 66% and 49% less risk of recurrence, respectively, compared to those undergoing ENDO. When comparing ULT to UFG directly, there was no significant difference of recurrence. Conclusion This retrospective multi‐institutional study of female urethral stricture demonstrates that patients undergoing endoscopic management have a higher risk of recurrence compared to those undergoing either urethroplasty with local flap or free graft.
Genomics combined with a protein informatics platform to assess a novel pathogenic variant c.1024 A>G (p.K342E) in OPA1 in a patient with autosomal dominant optic atrophy
Ahuja, Abhimanyu S. , Selvam, Pavalan , Vadlamudi, Charitha , Chopra, Hayley, Richter, John E. , Macklin, Sarah , Samreen, Ayesha , Helmi, Haytham , Mohammaad, Ahmed N., Hines, Stephanie L., Davila, Maria C., Caulfield, Thomas R. , Hines, Stephanie, Caulfield, Thomas R , Samreen, Ayesha , Ahuja, Abhimanyu , Atwal, Paldeep S

Mayo Clinic

Ophthalmic Genetics | September 17, 2020 | Volume: 41 | Issue: 6 | Pages: 563-569

10.1080/13816810.2020.1814344 | PMID 32940104 Get It

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Oh, Stephen T. , Gerds, Aaron T. , Verstovšek, Srđan , Miller, Carole B., Rivera, Candido E., Goel, Swati , Heaney, Mark , Arcasoy, Murat O. , Zhang, Yafeng , Ganz, Tomas , Kowalski, Mark , Brachmann, Carrie Baker, Gerds, Aaron T , Verstovsek, Srdan , Oh, Stephen T , Talpaz, Moshe , Gupta, Vikas , Mesa, Ruben A. , Fleischman, Angela G. , O'Connell, Casey Lee , Kawashima, Jun

Mayo Clinic

Blood Advances | September 11, 2020 | Volume: 4 | Issue: 18 | Pages: 4282-4291

10.1182/bloodadvances.2020002662 | PMID 32915978 Get It

Abstract Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 transfusion-dependent patients with MF, we explored mechanisms underlying the favorable activity of MMB on MF-associated iron-restricted anemia, including its impact on serum hepcidin levels, and markers of iron storage and availability, erythropoiesis, and inflammation. A transfusion-independent response (TI-R), defined as red blood cell transfusion independence (TI) ≥12 weeks at any time on study, occurred in 17 patients (41%; 95% confidence interval [CI], 26%-58%), including 14 patients (34%; 95% CI, 20%-51%) who achieved TI-R by week 24. In addition, 78% of TI nonresponse (TI-NR) patients achieved a ≥50% decrease in transfusion requirement for ≥8 weeks. Adverse events (AEs) were consistent with previous studies of MMB in MF, with cough, diarrhea, and nausea as the most common. Twenty-one patients experienced grade ≥3 AEs, most commonly anemia and neutropenia. Consistent with preclinical data, daily MMB treatment led to an acute and persistent decrease in blood hepcidin associated with increased iron availability and markers of erythropoiesis. Baseline characteristics associated with TI-R were lower inflammation and hepcidin as well as increased markers of erythropoiesis and bone marrow function. Overall, the study demonstrates that MMB treatment decreases hepcidin in conjunction with improving iron metabolism and erythropoiesis, suggesting a mechanistic explanation for the reduced transfusion dependency observed in transfusion-dependent MF patients treated with MMB, thereby addressing the key unmet medical need in the MF population.
C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy
Cook, Casey , Wu, Yanwei , Odeh, Hana M. , Gendron, Tania F. , Jansen‐West, Karen , Rosso, Giulia del, Yue, Mei, Jiang, Peizhou , Gomes, Edward, Tong, Jimei, Daughrity, Lillian M. , Avendano, Nicole M., Castanedes‐Casey, Monica , Shao, Wei , Oskarsson, Björn , Tomassy, Giulio Srubek, McCampbell, Alexander , Rigo, Frank , Zhang, Yong‐Jie , Petrucelli, Leonard , Cook, Casey N , Del Rosso, Giulia, Dickson, Dennis W , Shorter, James , Zhang, Yong-Jie , Petrucelli, Leonard , Oskarsson, Björn , Gendron, Tania F , Shao, Wei , Dickson, Dennis W. , Shorter, James

Mayo Clinic

Science Translational Medicine | September 2, 2020 | Volume: 12 | Issue: 559 | Pages: No page available

10.1126/scitranslmed.abb3774 | PMID 32878979 Get It

G 4 C 2 repeat–derived poly(GR) plays a key role in mediating TDP-43 mislocalization and aggregation in vitro and in vivo.